Afatinib, also know as BIBW 2992, is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. Afatinib is approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an angiokinase inhibitor.
Properties:
Appearance & Physical State: Off-White Solid
Density: 1.380g/cm3
Boiling Point: 676.917ºC at 760 mmHg
Melting Point: 100 - 102 °C
Flash Point: 363.186ºC
Refractive Index: 1.668
Related Products:
Afatinib dimaleate; Neratinib; Bosutinib; Bosutinib Intermediates; Bosutinib Monohydrate; Saracatinib; Dasatinib; NVP-BHG712; PP1; PP2; A-966492; G007-LK; SU6656; Tirbanibulin; TPX-0005